Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker INO
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Abigail P. Johnson | 15.36M | 14.5% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | FMR LLC | 15.36M | 14.5% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Phillip Gross | 3.43M | 4.0% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Robert Atchinson | 3.43M | 4.0% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Adage Capital Management, L.P. | 3.43M | 4.0% | SCHEDULE 13G/A ↗ |
| Aug 7, 2026 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | RA Capital Healthcare Fund, L.P. | 10.67M | 9.9% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Rajeev Shah | 10.67M | 9.9% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Peter Kolchinsky | 10.67M | 9.9% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | RA Capital Management, L.P. | 10.67M | 9.9% | SCHEDULE 13G ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Abigail P. Johnson | 8.45M | 10.3% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | FMR LLC | 8.45M | 10.3% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Vanguard Capital Management | 4.16M | 5.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Highbridge Capital Management LLC | 6.19M | 8.2% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Phillip Gross | 4.23M | 5.8% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Robert Atchinson | 4.23M | 5.8% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Adage Capital Management, L.P. | 4.23M | 5.8% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Abigail P. Johnson | 9.34M | 13.5% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | FMR LLC | 9.34M | 13.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Anand Parekh | 4.00M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Alyeska Fund GP, LLC | 4.00M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Alyeska Investment Group, L.P. | 4.00M | 6.0% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | The Vanguard Group | 3.32M | 5.0% | SCHEDULE 13G/A ↗ |
| Dec 8, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Janus Henderson Group PLC | 6.67M | 10.0% | SCHEDULE 13G/A ↗ |
| Dec 5, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Abigail P. Johnson | 9.85M | 14.8% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | FMR LLC | 9.85M | 14.8% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 2.80M | 5.3% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Janus Henderson Group PLC | 3.27M | 6.2% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Anand Parekh | 4.00M | 7.5% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Alyeska Fund GP, LLC | 4.00M | 7.5% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Alyeska Investment Group, L.P. | 4.00M | 7.5% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | David Kroin | 1.31M | 2.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 1.31M | 2.4% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Deep Track Capital, LP | 1.31M | 2.4% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Phillip Gross | 5.52M | 10.0% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Robert Atchinson | 5.52M | 10.0% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Adage Capital Management, L.P. | 5.52M | 10.0% | SCHEDULE 13G ↗ |
| Jul 17, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | BlackRock, Inc. | 537,627 | 1.5% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Jon M. Plexico | 1.43M | 3.8% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Stonepine GP, LLC | 1.43M | 3.8% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Stonepine Capital, L.P. | 1.43M | 3.8% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | Stonepine Capital Management, LLC | 1.43M | 3.8% | SCHEDULE 13G/A ↗ |
| Apr 30, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | The Vanguard Group | 2.03M | 5.5% | SCHEDULE 13G ↗ |
| Apr 17, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | BlackRock, Inc. | 2.32M | 6.3% | SCHEDULE 13G/A ↗ |
| Feb 10, 2025 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Highbridge Capital Management, LLC | 3.63M | 9.2% | SCHEDULE 13G ↗ |
| Feb 5, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | BlackRock, Inc. | 1.91M | 5.3% | SCHEDULE 13G/A ↗ |
| Jan 30, 2025 | SCHEDULE 13G/A (amended) | INO Inovio Pharmaceuticals, Inc. | The Vanguard Group | 1.67M | 4.6% | SCHEDULE 13G/A ↗ |
| Dec 23, 2024 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Jon M. Plexico | 1.92M | 5.2% | SCHEDULE 13G ↗ |
| Dec 23, 2024 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Stonepine GP, LLC | 1.92M | 5.2% | SCHEDULE 13G ↗ |
| Dec 23, 2024 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Stonepine Capital, L.P. | 1.92M | 5.2% | SCHEDULE 13G ↗ |
| Dec 23, 2024 | SCHEDULE 13G | INO Inovio Pharmaceuticals, Inc. | Stonepine Capital Management, LLC | 1.92M | 5.2% | SCHEDULE 13G ↗ |
50 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 10:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances